Pancreatic and Hepatic Oncology Research
Moving in Nature Medicine and Nature Reviews Drug Discovery.
- Moved, week to 23 Oct 2026
- 2
- Papers in 60 days
- 37
Rebuilt
Moved this week
Over 59% of pancreatic cancer patients treated with daraxonrasib develop resistance through RAS pathway alterations, including KRAS amplification and RTK upregulation.
- Open access
- 8 cites
Latest in Pancreatic and Hepatic Oncology Research
Newest first · last 60 days
A therapy-resistant CD44v9+ cancer stem cell population persists in pancreatic ductal adenocarcinoma tissues and organoid models despite treatment with cabozantinib and immunotherapy.
- Open access
- 1 cites
HtpG-high-expressing Escherichia coli (HHEC) is enriched in chronic pancreatitis patients and exacerbates disease via a macrophage-mediated pathway.
Guanine nucleotide depletion via IMPDH2 inhibition suppresses pancreatic cancer and enhances KRAS inhibitor efficacy, with depletion being irreversible and independent of KRAS pathways.
- Open access
- 5 cites
Increased MTFP1 expression promotes pancreatic ductal adenocarcinoma liver colonization by enhancing mitochondrial metabolism reprogramming through the ROS/PI3K/AKT/c-MYC/SLC1A5 pathway.
- Open access
- 7 cites
A blood-based microRNA assay combined with carbohydrate antigen 19-9 detects early-stage pancreatic ductal adenocarcinoma with 86.8% sensitivity in a large international study.
Asynchronous evolution of epithelial and stromal components distinguishes PanIN progression to pancreatic cancer, with stromal reprogramming being notably absent in early lesions.
- Open access
Distinct epithelial and fibroblast features are identified in pancreatitis and pancreatic ductal adenocarcinoma (PDAC) using multi-stromal organoid co-cultures.
- Open access
Exercise reduces stromal fibroblasts and inflammatory signals in pancreatic cancer, with a 50% decrease in αSMA+ cells linked to microbial metabolites.
- Open access
Implementing EHR-based risk models with imaging and blood tests detects pancreatic cancer early in 8.2% of high-risk adults aged 50-84.
- Open access
Targeting RAS mutations offers promising strategies for intercepting pancreatic cancer at its precancerous stage.
Reg-EXTL3 axis promotes nerve-cancer interactions in pancreatic ductal adenocarcinoma, with silencing reducing tumor progression and pain in mice.
Targeting multiple overlooked factors, the Heracles Protocol offers a comprehensive approach to make pancreatic ductal adenocarcinoma more treatable.
Serpine1 and Serpinb2 drive immune evasion in pancreatic ductal carcinoma by shaping immunosuppressive microenvironments in spatially restricted niches.
- Open access
Combining radiotherapy and immunotherapy offers a promising approach to improve survival in localized pancreatic ductal adenocarcinoma, despite current challenges.
Add Pancreatic and Hepatic Oncology Research as an interest in JClub
Browse JClub
Journals this month
- bioRxiv6131
- medRxiv1703
- PNAS447
- Sci Adv354
- JAMA262
- Environ Res230
- BMJ182
- Environ Pollution165
- Nat Commun161
- Science141
- Nature138
- Lancet128
- Cell Rep120
- NEJM119
- mBio107
- Plant Cell Environ107
- Curr Biol106
- J Exp Bot106
Topics moving, week to 23 Oct 2026
- Single-cell and spatial transcriptomics6
- Neuroinflammation and Neurodegeneration Mechanisms5
- Bacteriophages and microbial interactions5
- Gut microbiota and health5
- Genomics and Phylogenetic Studies4
- Cancer Genomics and Diagnostics4
- Cancer Immunotherapy and Biomarkers4
- Alzheimer's disease research and treatments3
- Inflammatory Bowel Disease3
- Influenza Virus Research Studies3